Phase 2
Completed N=64
E3 Breast Cancer Taxotere Combination
Source: ClinicalTrials.gov NCT00494481 ↗Enrolled (actual)
64
Serious AEs
41.9%
Results posted
May 2011
Primary outcomePrimary: Number of Patients With a Disease Progression Event — 24; 18 Participants
Summary
To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With a Disease Progression Event |
24; 18 | — |
Eligibility Criteria
Inclusion Criteria
- Females with histological/cytological confirmation of breast cancer.
- Subjects with a measurable lesion or bone lesions
Exclusion Criteria
- Previous radiotherapy within 6 weeks
- Significant cardiac events, arrhythmias or other cardiac conditions
Data sourced from ClinicalTrials.gov (NCT00494481). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.